Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: LncRNA MCF2L-AS1 aggravates the malignant development of colorectal cancer via targeting miR-105-5p/RAB22A axis

Fig. 1

MCF2L-AS1 is highly expressed in CRC cells and accelerates the progression of CRC. A. The expression of MCF2L-AS1 in COAD tissues and adjacent normal tissues was assessed via GEPIA database. B. MCF2L-AS1 expression was measured in CRC cell lines (HCT15, SW620, SW116 and LOVO) and human normal colon epithelial cells (NCM-460) by RT-qPCR. C. The interference efficiency of MCF2L-AS1 in HCT15 and SW116 cells was tested by RT-qPCR assay. D and E. Cell proliferation in HCT15 and SW116 cells after MCF2L-AS1 silencing was evaluated through IF staining and EdU assay. F and G. The migratory and invasive abilities of CRC cells upon MCF2L-AS1 silencing were evaluated through Transwell assays. H and I. Flow cytometry assay and caspase-3/8/9 activity analysis were utilized to test cell apoptosis upon MCF2L-AS1 silencing. J. The EMT process was assessed through IF assay after MCF2L-AS1 was silenced in HCT15 and SW116 cells. Adjustments of individual color channels were made on ‘Merge’ figures. The statistical analysis of Fig. 1B-I was tested with one-way ANOVA. *P < 0.05, **P < 0.01

Back to article page